Northwire Canada EditionThursday, October 15, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4% GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4%
Production / Operations

Zero Candida Achieves Design Freeze and Begins Prototype Production of ZC-001 Therapeutic Device

By The Northwire Desk — AI Analysis Oct 20, 2025 · 09:00 ZCT · 0.28 Zero Candida Technologies Inc.
ZCT · Price

Executive Summary

  • Zero Candida Technologies announced the design freeze of its ZC‑001 therapeutic device and the start of prototype production (50 units), with completion expected by Q1 2026.
  • The milestone advances the company’s regulatory pathway and positions it for upcoming clinical validation and potential market entry in the VVC treatment space.
  • Key design features—including a secure docking system, wireless encrypted data transfer, medical‑grade materials, and modular assembly—were finalized, supporting scalable manufacturing and future product extensions.

Key Details

  • Design Freeze: Final specifications locked for ZC‑001 device and its SMART docking/charging case.
  • Prototype Production: Initiated production of 50 prototype units; projected completion Q1 2026.
  • Device Functionality: AI‑enabled therapeutic platform combining blue‑light therapy, targeted drug delivery, and wireless diagnostics for at‑home treatment of Vulvo‑Vaginal Candidiasis (VVC).
  • Key Design Elements:
  • Docking system for automatic alignment, charging, sterilization, and dosing accuracy.
  • Wireless connectivity enabling encrypted real‑time data transmission to physicians and AI analytics.
  • Light‑guide indicators for discreet status communication.
  • Medical‑grade materials ensuring comfort, hygiene, and biocompatibility.
  • Modular assembly facilitating scalable manufacturing and future gynecologic applications.
  • Regulatory Implication: Design freeze is a critical step toward meeting regulatory requirements and advancing to clinical validation phases.
  • Market Context: VVC treatment market projected > US$2 billion by 2030; the device aims to address unmet needs, especially for recurrent and drug‑resistant cases.

Notable Quotes

“Achieving design freeze and starting prototype production marks a major advancement for Zero Candida as we move closer to delivering a much needed solution for women suffering from VVC,” – Eli Ben‑Haroosh, CEO.

“Every design decision was made with patient comfort and usability in mind… defines the technical standards for how ZC‑001 will be built and tested,” – Dr. Asher Holzer, CTO.

Read the original news release →

More from Zero Candida Technologies Inc.

Jun 24, 2026 · 08:00

Zero Candida announced officially been granted Patent No. 12654025B2 -- a meaningful milestone that reflects our commitment to innovation, technology, and long-term impact

Other Feb 17, 2026 · 08:00

Zero Candida Scales Production to 250 ISO 13485 Clinical-Grade Prototypes of ZC-001 Therapeutic Device

Production / Operations